CompletedNCT00827918
MK-8998, olanzapine or placebo for acute psychosis in schizophrenia
About this title
Read the official source —Researchers compared MK-8998, Comparator: Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–55
Understand this study
What did researchers investigate?
Researchers compared MK-8998, Comparator: Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMarch 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 216
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00827918
- Official title
Show the full official title
A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
Researchers compared MK-8998, Comparator: Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Merck Sharp & Dohme LLC.
Did this study involve medication?
Yes. The study involved medication, including MK-8998, Comparator: Olanzapine and Comparator: Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia